ERBB2 and breast carcinoma: In breast cancer, reduced KLK6 mRNA levels have been found relative to noncancerous tissue, but in TNBC and HER2‐positive cancer, there is an overexpression of KLK6 mRNA and KLK6 levels constitute an unfavorable marker for breast cancer (Haritos et al., 2018).